Monday, June 30, 2025 6/30/2025

A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer

Award Number: R61CA278459
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer - Abstract Thyroid cancer patients with distant metastases or unresectable disease have poor likelihood of long-term survival. Radioactive iodine (RAI) can specifically and systemically eradicate malignant thyroid cancer cells that have spread throughout the body through metastasis. However, 5-15% of all thyroid cancer patients eventually progress to RAI-refractory status, which has the poorest prognosis of all thyroid cancer cases. Refractory disease occurs when thyroid tumor cells lose their innate ability to take up and concentrate RAI. Recent clinical studies have shown that kinase inhibitors and other drugs can reverse this effect by redifferentiating refractory tumor cells, thus restoring the cellular machinery required to concentrate RAI. However, this redifferentiation strategy remains challenging to optimize and deploy clinically. The reasons for this include the small number of patients eligible, the heterogeneity of the disease, the toxicity of targeted kinase therapies, and the lack of robust biomarkers. This project will develop papillary thyroid carcinoma organoids to study and individualize the use of redifferentiation agents to restore RAI uptake in RAI-refractory patients. In the first Aim, we develop a novel automated and high-throughput assay to measure RAI uptake in thousands of tumor organoid cultures. The assay will be optimized to achieve specific performance goals, including throughput, linearity, limit of detection, and reproducibility. In the second Aim, we will demonstrate the assay in a small pilot study of 10 patients. The panel of tumor organoids, which will include both RAI-sensitive and refractory disease, will be used to screen a library of relevant drugs on the basis of RAI uptake. Using the approach, we will optimize dosing and scheduling of the treatments towards the eventual goal of individualizing therapy to maximize efficacy while minimizing the adverse side effects of kinase inhibitors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $216,546 )
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Biology Research	001	3	5/30/2025	NON-COMPETING CONTINUATION	$21,655
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Biology Research	000	3	4/30/2025	NON-COMPETING CONTINUATION	$194,891
														Subtotal = $216,546

Issue Date FY: 2024 ( Subtotal = $205,719 )
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Biology Research	000	2	4/15/2024	NON-COMPETING CONTINUATION	$205,719
														Subtotal = $205,719

Issue Date FY: 2023 ( Subtotal = $216,862 )
2023	2023	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Biology Research	000	1	5/17/2023	NEW	$216,862
														Subtotal = $216,862

Grand Total All Awards = $639,127

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer

Award Number: R61CA278459

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer